Iron Bisglycinate

Iron bisglycinate delivers ferrous iron (Fe²⁺) chelated to two glycine molecules, enabling absorption via the intestinal PEPT-1 proton-coupled peptide transporter rather than the conventional, saturable DMT-1 iron channel, which dramatically increases uptake efficiency. A 2023 systematic review and meta-analysis of 17 RCTs encompassing over 1,100 patients found ferrous bisglycinate raised hemoglobin by a standardized mean difference of 0.54 g/dL (95% CI 0.15–0.94, P<0.01) versus comparator iron supplements, while simultaneously reducing gastrointestinal adverse events by 64% (IRR 0.36, 95% CI 0.17–0.76, P<0.01).

Origin & History

Iron bisglycinate is a fully synthetic nutraceutical chelate developed in the latter half of the 20th century, with no geographic or botanical origin. It is manufactured by reacting ferrous iron (Fe²⁺) with two molecules of the amino acid glycine under controlled conditions to form a stable, neutral ring structure. The compound was pioneered commercially under the Ferrochel® trademark by Albion Minerals (now Balchem) and is produced in pharmaceutical and food-grade manufacturing facilities worldwide.

Historical & Cultural Context

Iron bisglycinate has no history of use in traditional medicine systems such as Ayurveda, Traditional Chinese Medicine, or Western herbalism, as it is an entirely modern synthetic nutraceutical with no pre-20th-century precedent. The compound was developed in the context of mid-to-late 20th century research into amino acid chelation technology by Albion Laboratories (later Albion Minerals, now part of Balchem Corporation), which pioneered the commercial production of mineral amino acid chelates and registered the Ferrochel® trademark. Its development was driven by the global public health burden of iron deficiency anemia — the world's most prevalent nutritional deficiency affecting an estimated 1.2 billion people — and the well-documented intolerability of first-generation iron supplements such as ferrous sulfate. Today it is recognized by regulatory bodies including the FDA (GRAS status in certain food applications) and is incorporated into WHO-aligned strategies for IDA management in vulnerable populations including pregnant women, infants, and children in both high- and low-income countries.

Health Benefits

- **Iron Deficiency Anemia (IDA) Correction**: Ferrous bisglycinate replenishes depleted iron stores and restores hemoglobin synthesis by supplying Fe²⁺ for heme incorporation into erythrocytes; meta-analytic data confirm a significant 0.54 g/dL hemoglobin increase versus comparators across 17 RCTs.
- **Superior Gastrointestinal Tolerability**: The chelated structure limits free ionic iron in the gut lumen, reducing oxidative mucosal irritation; clinical evidence shows a 64% reduction in GI adverse events (nausea, constipation, bloating) compared to conventional iron salts.
- **Pregnancy and Maternal Iron Support**: Iron bisglycinate is well-tolerated during all trimesters, supporting fetal erythropoiesis, placental oxygen delivery, and maternal ferritin repletion without the nausea commonly associated with ferrous sulfate supplementation.
- **Restoration of Cellular Energy Metabolism**: Absorbed iron reconstitutes iron-sulfur (Fe-S) clusters within mitochondrial complexes I, II, and III of the electron transport chain, restoring ATP synthesis capacity and reducing fatigue even in non-anemic iron-depleted individuals.
- **Neurotransmitter Cofactor Replenishment**: Iron is an obligate cofactor for tyrosine hydroxylase and tryptophan hydroxylase, the rate-limiting enzymes in dopamine and serotonin biosynthesis respectively; correction of iron deficiency with bisglycinate has been associated with improvements in mood, cognitive function, and restless leg syndrome symptoms.
- **Ferritin and Iron Store Repletion in Children**: In pediatric IDA trials using 3–6 mg/kg/day elemental iron, ferrous bisglycinate significantly elevated serum ferritin and mean corpuscular hemoglobin (MCH) — indices of iron store recovery — unlike polymaltose iron, with ferritin response negatively correlated with baseline hemoglobin severity.
- **Fatigue Resolution in Non-Anemic Iron Deficiency**: Clinical reviews report that iron bisglycinate resolves fatigue and exercise intolerance associated with depleted ferritin stores (without frank anemia), a population often undertreated with conventional iron salts due to poor tolerability.

How It Works

Iron bisglycinate is absorbed intact or near-intact across the intestinal brush border primarily via the PEPT-1 (SLC15A1) proton-coupled dipeptide transporter expressed in duodenal and proximal jejunal enterocytes, a high-capacity route that bypasses the rate-limiting and competitively inhibited divalent metal transporter 1 (DMT-1/SLC11A2) used by ionic iron salts, thereby achieving substantially higher and more consistent absorption. Once inside the enterocyte, the glycine ligands are cleaved by intracellular peptidases, liberating free Fe²⁺, which is either stored as ferritin or exported basolaterally via ferroportin-1 (SLC40A1) in a process regulated by hepcidin; this hepcidin-mediated regulation means absorption scales inversely with body iron status, providing a physiologic safety buffer against overload. Systemically, transferrin binds the released Fe²⁺ and delivers it to erythroid precursors in bone marrow for hemoglobin synthesis, to hepatocytes for ferritin storage, and to all aerobic cells for reconstitution of iron-sulfur clusters in mitochondrial respiratory chain complexes, ribonucleotide reductase activity, and metalloenzyme function including the hydroxylases critical for catecholamine and indoleamine neurotransmitter synthesis.

Scientific Research

The evidence base for iron bisglycinate is robust relative to most nutraceutical minerals, anchored by a 2023 systematic review and meta-analysis of 17 randomized controlled trials (total n > 1,100) that quantified hemoglobin response and GI tolerability versus comparator iron supplements, yielding statistically significant pooled effect sizes with narrow confidence intervals. Pediatric RCT data from IDA trials using 3–6 mg/kg/day for 45 days demonstrated superiority over iron polymaltose complex on ferritin and MCH outcomes, and mechanistic absorption studies using stable iron isotopes have confirmed the PEPT-1-mediated uptake advantage in human subjects. The evidence is strongest for hemoglobin repletion and GI tolerability in pregnant women and children with IDA, while data on fatigue in non-anemic populations, cognitive outcomes, and long-term safety beyond 20-week trial durations remain limited and require larger, longer studies. Overall the ingredient earns a strong evidence classification for its primary indication (IDA treatment and prevention) but a moderate classification for secondary endpoints such as exercise performance and mood, where trials are smaller and mechanistic inference is more prominent than direct clinical proof.

Clinical Summary

The most definitive clinical evidence derives from the 2023 meta-analysis of 17 RCTs in predominantly pregnant and pediatric populations, which demonstrated a standardized mean difference in hemoglobin of +0.54 g/dL (95% CI 0.15–0.94, P<0.01) and a 64% reduction in gastrointestinal adverse event incidence (IRR 0.36, 95% CI 0.17–0.76, P<0.01) for ferrous bisglycinate versus comparator iron supplements over treatment durations of 4–20 weeks. Pediatric IDA trials (3–6 mg/kg/day elemental iron for 45 days) showed significant improvements in ferritin, MCH, MCV, RDW, and hemoglobin, with ferritin response inversely correlated with baseline hemoglobin severity, distinguishing bisglycinate from polymaltose iron which failed to raise ferritin comparably. Effect sizes are clinically meaningful for anemia correction, and the GI tolerability advantage is consistently reproduced across populations, supporting preferential use in groups prone to iron supplement intolerance (pregnant women, elderly, patients with GI conditions). Confidence in the primary outcomes (hemoglobin repletion and GI tolerability) is high; confidence in secondary outcomes such as neurocognitive improvement, fatigue in non-anemic subjects, and long-term iron store maintenance is moderate, based on smaller or less rigorous evidence.

Nutritional Profile

Iron bisglycinate is not a whole food and does not contribute macronutrients, fiber, or a broad micronutrient profile. Each molecule delivers one atom of elemental ferrous iron (Fe²⁺, atomic weight 55.85 g/mol) and two molecules of glycine (the simplest amino acid, non-essential); at a 14 mg elemental iron dose, the co-delivered glycine mass is negligible (approximately 30–35 mg total, nutritionally insignificant). The bioavailability of the iron itself is the defining nutritional characteristic: PEPT-1-mediated absorption produces substantially higher fractional iron uptake than ferrous sulfate (which relies on DMT-1), with studies suggesting relative bioavailability ratios of 2:1 to 4:1 versus sulfate in humans under controlled conditions. Absorption is further regulated by body iron status (hepcidin axis), enhancing safety; the presence of dietary phytates, calcium, polyphenols, and proton pump inhibitors can reduce but do not abolish absorption given the PEPT-1 route.

Preparation & Dosage

- **Capsules/Tablets (Standard Prevention Dose)**: 14–18 mg elemental iron daily (e.g., Ferrochel® 14 mg capsule); suitable for maintenance in at-risk adults and pregnancy supplementation.
- **Capsules/Tablets (Therapeutic Repletion Dose — Adults)**: 25–29 mg elemental iron once or twice daily for active IDA correction; clinical trials used this range over 4–20 weeks.
- **Pediatric Therapeutic Dose**: 3–6 mg/kg/day elemental iron (as ferrous bisglycinate) divided into one or two daily doses for 45–90 days for IDA in children aged 1–12 years, per clinical trial protocols.
- **Timing**: Best absorbed on an empty stomach or with a small meal low in phytates and calcium; if GI sensitivity occurs, taking with a light meal is acceptable given the reduced GI irritation profile of this form.
- **Vitamin C Co-administration**: Pairing with 50–100 mg ascorbic acid can further enhance Fe²⁺ stability in the GI lumen, though the chelated form already resists oxidation better than iron salts.
- **Standardization**: Commercial Ferrochel® and equivalent chelates are standardized to confirmed ferrous bisglycinate chelate structure with documented elemental iron content per dose (14 mg, 25 mg, or 29 mg); verify Certificate of Analysis for elemental iron percentage.
- **Fortified Food Applications**: Used at 2–10 mg elemental iron per serving in functional foods and infant formulas where taste and color neutrality are required.

Synergy & Pairings

Vitamin C (ascorbic acid, 50–100 mg co-administered) synergizes with iron bisglycinate by maintaining Fe²⁺ in its reduced, absorbable state within the intestinal lumen and by enhancing ferroportin-mediated basolateral export, though the chelated structure already confers greater acid stability than ionic salts; this pairing is standard in many commercial formulations. Folate (vitamin B9) and vitamin B12 are logical co-supplementation partners when iron bisglycinate is used to treat megaloblastic-overlap anemias of pregnancy, as all three nutrients are required for erythropoiesis — iron for hemoglobin heme, B12 and folate for DNA synthesis in erythroid precursors. Copper (as bisglycinate or gluconate, 1–2 mg) is an underrecognized synergist, as ceruloplasmin (a copper-dependent ferroxidase) is required to oxidize Fe²⁺ to Fe³⁺ for transferrin loading and systemic iron transport, making copper sufficiency a prerequisite for full iron utilization.

Safety & Interactions

At standard supplemental doses of 14–29 mg elemental iron daily, iron bisglycinate is well-tolerated with a 64% lower incidence of gastrointestinal adverse events (nausea, constipation, epigastric discomfort, dark stools) compared to ionic iron salts in meta-analytic data; doses up to 6 mg/kg/day in children for 45 days have been documented as safe in clinical trials. The primary absolute contraindication is hereditary hemochromatosis, iron overload disorders (e.g., thalassemia major, sideroblastic anemia), or any clinical state with elevated transferrin saturation, as bisglycinate's enhanced bioavailability could accelerate iron loading. Clinically relevant drug interactions include tetracycline and fluoroquinolone antibiotics (iron chelates the drug, reducing antibiotic absorption — separate doses by at least 2 hours), levothyroxine (iron reduces thyroid hormone absorption — separate by 4 hours), proton pump inhibitors and antacids (reduce but do not abolish bisglycinate absorption due to partial pH independence of PEPT-1), and levodopa (impaired absorption). Iron bisglycinate is considered safe and is used intentionally in pregnancy supplementation; there are no established upper tolerable intake level deviations for this chelated form versus elemental iron (the tolerable upper intake level for iron is 45 mg/day for adults per Institute of Medicine guidelines), and long-term safety data beyond 20-week trial durations have not been formally published.